[1]
|
Walker, B.A., et al. (2018) Identification of Novel Mutational Drivers Reveals Oncogene Dependencies in Multiple My-eloma. Blood, 132, 587-597. https://doi.org/10.1182/blood-2018-08-870022
|
[2]
|
Uamani, S.Z., Diel, J., Ito, T., Mehra, M., Khan, I. and Lam, A. (2017) Daratumumab Monotherapy Compared with Historical Control Data in Heavily Pretreated and Highly Refarctory Patients with Multiple Myeloma: An Adjusted Treatment Comparison. American Jour-nal of Hematology, 92, e146-e152. https://doi.org/10.1002/ajh.24781
|
[3]
|
黄月华, 潘崚. 硼替佐米的作用机制、临床应用及其疗效研究进展[J]. 实用诊断与治疗杂志, 2008(4): 280-282.
|
[4]
|
Guerrero-Garcia, T.A., Mogollon, R.J. and Castillo, J.J. (2017) Bortezomib in Plasmablastic Lymphoma: A Glimpse of Hope for a Hard-to-Treat Disease. Leukemia Research, 62, 12-16. https://doi.org/10.1016/j.leukres.2017.09.020
|
[5]
|
索传健, 周嘉俊, 顾民, 谭若芸. 硼替佐米通过下调smad泛素化调节因子2拮抗TNF-α诱导的肾小管上皮细胞表型转分化[J]. 中华器官移植杂志, 2018, 39(4): 232-237.
|
[6]
|
钟启, 刘爽, 朱阳敏, 谭友平, 郑丽玲, 欧瑞明. 异环磷酰胺、多柔比星脂质体、地塞米松联合方案对复发/难治多发性骨髓瘤有无髓外浆细胞瘤患者的疗效对比[J]. 中国医师进修杂志, 2018, 41(4): 329-332.
|
[7]
|
王欢, 赵真, 张滔, 马清, 血液, 熊梅. 硼替佐米联合地塞米松治疗老年多发性骨髓瘤的疗效及对免疫抑制因子、免疫细胞水平的影响[J]. 海南医学院学报, 2017, 23(2): 232-235.
|
[8]
|
李俊, 刘英杰, 宋庆. 硼替佐米为主的化疗方案联合苯达莫司汀治疗多发性骨髓瘤的临床研究[J]. 中国实用医刊, 2020, 47(13): 95-99.
|
[9]
|
Xu, M. (2017) Immunomodulatory Drugs (IMiDs) in Multiple Myeloma: Mechanism of Action and Clinical Implications. Boston University, Boston.
|
[10]
|
Richardson, P.G., Weller, E., Lonial, S., et al. (2010) Lenalidomide, Bortezomib, and Dexamethasone Combination Therapy in Patients with Newly Diagnosed Multiple Myeloma. Blood, 116, 679-686.
https://doi.org/10.1182/blood-2010-02-268862
|
[11]
|
Zhou, L., Yu, W., Jayabalan, D.S., et al. (2020) Caspase-8 In-hibition Prevents the Cleavage and Degradation of E3 Ligase Substrate Receptor Cereblon and Potentiates Its Biological Function. Frontiers in Cell and Developmental Biology, 8, Article 605989. https://doi.org/10.3389/fcell.2020.605989
|
[12]
|
Zhou, L., Huang, X., Niesvizky, R., Pu, Z. and Xu, G. (2021) Caspase-8 Regulates the Anti-Myeloma Activity of Bortezomib and Lenalidomide. American Society for Pharmacology and Experimental Therapeutics, 379, 303-309.
https://doi.org/10.1124/jpet.121.000818
|
[13]
|
Siegel, D., Martin, T., Nooka, A., et al. (2013) Integrated Safety Pro-file of Single-Agent Carfilzomib: Experience from 526 Patients Enrolled in 4 Phase II Clinical Studies. Haematologica, 98, 1753-1761.
https://doi.org/10.3324/haematol.2013.089334
|
[14]
|
Kuhn, D.J., Voorhees, P.M., Strader, J.S., et al. (2005) Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway against Pre-Clinical Models of Multiple Myeloma. Blood, 106, 1576.
https://doi.org/10.1182/blood.V106.11.1576.1576
|
[15]
|
Bal, S., Landau, H., Shah, G., et al. (2020) Stem Cell Mo-bilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. Bi-ology of Blood and Marrow Transplantation, 26, 1394-1401.
https://doi.org/10.1016/j.bbmt.2020.04.011
|
[16]
|
罗涛, 夏海龙. 卡非佐米治疗多发性骨髓瘤的疗效及安全性的系统评价[J]. 中国实验血液学杂志, 2019, 27(6): 1887-1893. https://doi.org/10.19746/j.cnki.issn1009-2137.2019.06.029
|
[17]
|
Richardson, P.G., Baz, R., Wang, M., et al. (2014) Phase 1 Study of Twice-Weekly Ixazomib, an Oral Proteasome Inhibitor, in Relapsed/Refractory Multiple Myeloma Pa-tients. Blood, 124, 1038-1046.
https://doi.org/10.1182/blood-2014-01-548826
|
[18]
|
Kumar, S.K., Laplant, B., Roy, V., et al. (2015) Phase 2 Trial of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. Blood Cancer Journal, 5, e338. https://doi.org/10.1038/bcj.2015.60
|
[19]
|
Moreau, P., Masszi, T., et al. (2016) Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. The New England Journal of Medicine, 374, 1621-1634. https://doi.org/10.1056/NEJMoa1516282
|
[20]
|
Hou, J., Jin, J., Xu, Y., et al. (2017) Randomized, Double- Blind, Placebo-Controlled Phase III Study of Ixazomib Plus Lenalidomide-Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: China Continuation Study. Journal of Hematology & Oncology, 10, Article No. 137. https://doi.org/10.1186/s13045-017-0501-4
|
[21]
|
Kumar, S.K., Buadi, F.K., Betsy, L.P., et al. (2018) Phase 1/2 Tri-al of Ixazomib, Cyclophosphamide and Dexamethasone in Patients with Previously Untreated Symptomatic Multiple Myeloma. Blood Cancer Journal, 8, Article No. 70.
https://doi.org/10.1038/s41408-018-0106-3
|
[22]
|
Richardson, P.G., Hofmeister, C.C., Rosenbaum, C.A., et al. (2018) Twice-Weekly Ixazomib in Combination with Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. British Journal of Haematology, 182, 231-244. https://doi.org/10.1111/bjh.15394
|
[23]
|
Spencer, A., Harrison, S., Zonder, J., et al. (2018) A Phase 1 Clinical Trial Evaluating Marizomib, Pomalidomide and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma (NPI-0052-107): Final Study Results. British Journal of Haematology, 180, 41-51. https://doi.org/10.1111/bjh.14987
|
[24]
|
Badros, A., Singh, Z., Dhakal, B., et al. (2017) Marizomib for Central Nervous System-Multiple Myeloma. British Journal of Haematology, 177, 221-225. https://doi.org/10.1111/bjh.14498
|
[25]
|
Carpenter, R.O., Evbuomwan, M.O., Pit Taluga, S., et al. (2013) B-Cell Maturation Antigen Is a Promising Target for Adoptive T-Cell Therapy of Multiple Myeloma. Clinical Cancer Research, 19, 2048-2060.
|
[26]
|
Ali, S.A., Shi, V., Maric, I., et al. (2016) T Cells Expressing an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Multiple Myeloma. Blood, 128, 1688-1700.
|
[27]
|
Zhao, W.-H., Liu, J., Wang, B.-Y., et al. (2018) A Phase 1, Open-Label Study of LCAR-B38M, a Chimeric Antigen Receptor T Cell Therapy Directed against B Cell Maturation Antigen, in Patients with Relapsed or Refractory Multiple Myeloma. Journal of He-matology & Oncology, 11, Article No. 141.
|
[28]
|
Drent, E., Themeli, M., Poels, R., et al. (2017) A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. Molecular Therapy, 25, 1946-1958.
|
[29]
|
Tang, F., Lu, Y., Ge, Y., Shang, J. and Zhu, X. (2020) Infusion of Chimeric Antigen Receptor T Cells against Dual Targets of CD19 and B-Cell Maturation Antigen for the Treatment of Refractory Multiple Myeloma. Journal of International Medical Research, 48, 112-119. https://doi.org/10.1177/0300060519893496
|
[30]
|
Levin, A.G., Slobodkin, M.R., Waks, T., et al. (2020) Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity. Cancer Immunology Research, 8, 1485-1495.
|
[31]
|
Wang, X., Walter, M., Urak, R., et al. (2018) Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells against Multiple Myeloma. Clinical Cancer Research, 24, 106-119.
https://doi.org/10.1158/1078-0432.CCR-17-0344
|
[32]
|
王芳侠, 李月, 曹星梅, 张王刚, 古流芳. 沙利度胺联合改良VAD方案治疗多发性骨髓瘤临床疗效观察[J]. 现代肿瘤医学, 2015, 23(17): 2495-2497.
|
[33]
|
朱小凤, 李晓明, 唐君玲. 沙利度胺片联合硼替佐米注射剂治疗老年多发性骨髓瘤患者的临床研究[J]. 中国临床药理学杂志, 2020, 36(15): 2225-2228. https://doi.org/10.13699/j.cnki.1001-6821.2020.15.019
|
[34]
|
唐雪娟, 任莉. 低剂量沙利度胺联合常规化疗治疗多发性骨髓瘤的临床分析[J]. 中国生化药物杂志, 2014, 34(4): 113-115.
|
[35]
|
Barlogie, B. (2001) Introduction to Therapies in Multiple Myeloma. Seminars in Hematology, 38, 201-202.
https://doi.org/10.1016/S0037-1963(01)90010-1
|
[36]
|
Moreau, P., Miguel, J.S., Sonneveld, P., et al. (2017) Multi-ple Myeloma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 28, iv52-iv61. https://doi.org/10.1093/annonc/mdx096
|
[37]
|
Dimopoulos, M.A., Sagar, L., Betts, K.A., et al. (2018) Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Fol-low-Up and Analysis of Relative Progression-Free Survival from the Randomized ELOQUENT-2 Trial. Cancer, 124, 4032-4043. https://doi.org/10.1002/cncr.31680
|